September 21, 2023 10:36 AM EDT

Hepalys to develop Inventiva’s NASH treatment; Everest licenses Kezar’s autoimmune drug

Anna Brown

News Reporter

Hepalys Pharma said Thursday it will develop and commercialize Inventiva’s nonalcoholic steatohepatitis (NASH) treatment in Japan and South Korea, paying …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Hepalys to develop Inventiva’s NASH treatment; Everest licenses Kezar’s autoimmune drug

Anna Brown

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

He­palys to de­vel­op In­ven­ti­va’s NASH treat­ment; Ever­est li­cens­es Kezar’s au­toim­mune drug

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Hepalys to develop Inventiva’s NASH treatment; Everest licenses Kezar’s autoimmune drug